Background
Methods
Patients
Study design
Efficacy and safety measures
Opsonophagocytic assays
Statistical analysis
Results
Total baricitinib (N = 106) | |
---|---|
Age, years, mean (SD) | 55.1 (11.5) |
< 65 years, n (%) | 82 (77) |
≥ 65 years, n (%) | 24 (23) |
Female, n (%) | 85 (80) |
Race, n (%) | |
White | 89 (84) |
Black/African American | 15 (14) |
Asian | 1 (1) |
Multiple or other | 1 (1) |
Duration of RA diagnosis, years, mean (SD) | 12.1 (9.3) |
MTX use, n (%) | |
Without MTX | 12 (11) |
MTX-treated | 94 (89) |
Weekly dose (mg/week), mean (SD) | 18.2 (6.6) |
Current corticosteroid use, n (%) | 32 (30) |
Daily dose (mg/day), mean (SD) | 6.2 (2.7) |
Weight, kg, mean (SD) | 87.6 (21.7) |
Swollen joint count, of 66, mean (SD) | 3.7 (4.7) |
Tender joint count, of 68, mean (SD) | 5.0 (9.0) |
hsCRP, mg/L, mean (SD) | 9.3 (15.2) |
HAQ-DI, mean (SD), (range 0–3) | 0.9 (0.6) |
DAS28-CRP, mean (SD) (range 2–10) | 2.9 (1.1) |
CDAI, mean (SD) | 8.9 (8.8) |
SDAI, mean (SD) | 9.9 (8.8) |
Physician’s global assessment of disease activity (0–100), mean (SD) | 14.2 (14.6) |
Humoral responses at weeks 5 and 12
PCV-13 | TTV | |
---|---|---|
Overall baricitinib group (N = 106) | 70 (68) | 44 (43) |
Concomitant corticosteroids | ||
Yes (N = 31) | 22 (71) | 16 (52) |
No (N = 72) | 48 (67) | 28 (39) |
Age group | ||
Patients < 65 years (N = 80) | 59 (74) | 37 (46) |
Patients ≥ 65 years (N = 23) | 11 (48) | 7 (32) |
SDAI prior to vaccination | ||
≤ 3.3 (N = 21) | 13 (62) | 11 (55) |
> 3.3 and ≤ 11 (N = 47) | 34 (72) | 20 (43) |
> 11 (N = 32) | 21 (66) | 13 (41) |
Baricitinib dose | ||
2 mg (N = 16) | 11 (69) | 5 (33) |
4 mg (N = 87) | 59 (68) | 39 (45) |
IgG antibody concentrations and GMFR
OI responses
Serotype 4 | Serotype 6B | Serotype 14 | Serotype 23F | |
---|---|---|---|---|
Overall baricitinib group (N = 106) | 74 (76) | 76 (76) | 47 (47) | 73 (73) |
Concomitant corticosteroids | ||||
Yes (N = 31) | 27 (87) | 26 (84) | 14 (45) | 20 (65) |
No (N = 72) | 47 (70) | 50 (72) | 33 (48) | 53 (77) |
Age group | ||||
Patients < 65 years (N = 80) | 61 (81) | 66 (86) | 40 (52) | 58 (75) |
Patients ≥ 65 years (N = 23) | 13 (57) | 10 (43) | 7 (30) | 15 (65) |
SDAI prior to vaccination | ||||
≤ 3.3 (N = 21) | 14 (70) | 16 (76) | 11 (52) | 16 (76) |
> 3.3 and ≤ 11 (N = 47) | 36 (82) | 34 (76) | 24 (53) | 29 (64) |
> 11 (N = 32) | 23 (74) | 25 (81) | 11 (35) | 26 (84) |
Dose | ||||
2 mg (N = 16) | 11 (73) | 11 (73) | 9 (60) | 9 (60) |
4 mg (N = 87) | 63 (76) | 65 (76) | 38 (45) | 64 (75) |
Baricitinib (N = 106) | Baseline | Week 5 | Week 12 | |
---|---|---|---|---|
Immunoglobulin (μg/mL) | ||||
Serotype 4 | Geometric mean (95% CI) | 0.48 (0.41, 0.56) | 1.39 (1.05, 1.83) | 1.20 (0.91, 1.59) |
Fold increase (95% CI) | 2.8 (2.2, 3.6)* | 2.6 (2.0, 3.2)* | ||
Serotype 6B | Geometric mean (95% CI) | 0.89 (0.72, 1.12) | 3.32 (2.37, 4.63) | 3.10 (2.22, 4.35) |
Fold increase (95% CI) | 3.6 (2.8, 4.5)* | 3.2 (2.6, 4.0)* | ||
Serotype 14 | Geometric mean (95% CI) | 1.71 (1.30, 2.25) | 4.19 (3.12, 5.64) | 4.66 (3.45, 6.28) |
Fold increase (95% CI) | 2.5 (2.0, 3.2)* | 2.5 (1.9, 3.2)* | ||
Serotype 23F | Geometric mean (95% CI) | 0.80 (0.65, 0.99) | 2.89 (2.02, 4.14) | 2.86 (2.02, 4.05) |
Fold increase (95% CI) | 3.5 (2.7, 4.5)* | 3.4 (2.7, 4.4)* | ||
OI | ||||
Serotype 4 | Geometric mean (95% CI) | 92.1 (64.8131.0) | 1717.9 (1166.0, 2531.1) | 1016.8 (688.7, 1501.1) |
Fold increase (95% CI) | 18.2 (11.8, 28.0)* | 11.4 (7.5, 17.2)* | ||
Serotype 6B | Geometric mean (95% CI) | 153.8 (103.1, 229.4) | 2153.0 (1431.3, 3238.7) | 1519.0 (1029.2, 2241.9) |
Fold increase (95% CI) | 13.2 (8.5, 20.4)* | 9.0 (6.0, 13.4)* | ||
Serotype 14 | Geometric mean (95% CI) | 270.2 (176.8, 413.1) | 1328.2 (934.2, 1888.3) | 1152.0 (811.6, 1635.2) |
Fold increase (95% CI) | 4.9 (3.2, 7.5)* | 3.8 (2.5, 5.7)* | ||
Serotype 23F | Geometric mean (95% CI) | 50.1 (35.1, 71.5) | 627.2 (390.5, 1007.3) | 489.3 (314.9, 760.3) |
Fold increase (95% CI) | 12.1 (8.0, 18.5)* | 9.3 (6.3, 13.8)* |
Association between serotype-specific pneumococcal IgG and OI responses
Serotype 4 N = 98 | Serotype 6B N = 100 | Serotype 14 N = 100 | Serotype 23F N = 100 | |
---|---|---|---|---|
≥ 2-fold increase in pneumococcal IgG and functional OI | 46 (47) | 57 (57) | 32 (32) | 56 (56) |
≥ 2-fold increase in pneumococcal IgG, but not functional OI | 4 (4) | 6 (6) | 8 (8) | 3 (3) |
≥ 2-fold increase in functional OI, but not pneumococcal IgG | 28 (29) | 19 (19) | 15 (15) | 17 (17) |
< 2-fold increase in both pneumococcal IgG and functional OI | 20 (20) | 18 (18) | 45 (45) | 24 (24) |